title: [Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
abstract: OBJECTIVE
  Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis. This study was undertaken to evaluate the therapeutic effects of concurrent chemo-radiation therapy in advanced hepatocellular carcinoma with portal vein thrombosis.
  
  
  METHODS
  A total of 54 patients with advanced hepatocellular carcinoma (TNM stage IVa) were enrolled. Nineteen patients were treated with external beam radiotherapy (4,500 cGy/ 5 weeks) and intrahepatic arterial 5-FU infusion (500 mg on 1-5 day and 30-35 day, respectively) via implanted chemoport. The others were treated with intrahepatic arterial cisplatin infusion (80 mg/m(2)).
  
  
  RESULTS
  In patients treated with concurrent chemo-radiation therapy, response rates at 2nd and 6th months were 42.1% and 26.3%, respectively. In patients treated with intrahepatic arterial cisplatin therapy, response rates at 2nd and 6th months were 2.9% and 0%, respectively. The median survival time was 11.6 months in concurrent chemo-radiation therapy and 4.8 months in intrahepatic arterial cisplatin infusion therapy. Concurrent chemo-radiation therapy produced better response rates and longer survival time than those of intrahepatic arterial cisplatin infusion therapy (p<0.05).
  
  
  CONCLUSIONS
  Concurrent chemo-radiation therapy achieved favorable results in advanced hepatocellular carcinoma with portal vein thrombosis and can be considered as a treatment option for the management of advanced hepatocellular carcinoma.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. gihankhys@yonsei.yumc.ac.kr
authors.forename: Jin Suk
authors.initials: JS
authors.lastname: Kim
authors.forename: Kwang Hyub
authors.initials: KH
authors.lastname: Han
authors.forename: Do Yun
authors.initials: DY
authors.lastname: Lee
authors.forename: Jin Sil
authors.initials: JS
authors.lastname: Seong
authors.forename: Young Hoon
authors.initials: YH
authors.lastname: Youn
authors.forename: Jae Youn
authors.initials: JY
authors.lastname: Cheong
authors.forename: Sang Hoon
authors.initials: SH
authors.lastname: Ahn
authors.forename: Chae Yoon
authors.initials: CY
authors.lastname: Chon
authors.forename: Young Myoung
authors.initials: YM
authors.lastname: Moon
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000150:complications / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D011379:Prognosis; D020246:Venous Thrombosis / Q000150:complications*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin; D005472:Fluorouracil